Tumor immune response

CCR4-expresssing regulatory T cells is also stimulated via glioma cell secretion of CCL2. This may be an important mechanism whereby gliomas suppress anti-tumor immune responses and evade immune detection (Jordan et al. 2008). 

Dileo J, et al. Lipid-protamine-DNA-mediated antigen delivery to antigen presenting cells results in enhanced anti-tumor immune responses. Mol Ther 2003 7 640. 

Brunner, C., Seiderer, J., Schlamp, A, Bidlingmaier, M., Eigler, A, Haimerl, W. et al. (2000) Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol., 165, 6278-6286. 

Peptides eliciting anti-tumor immune responses... 

Comes A, Di Carlo E, Musiani P, Rosso O, Meazza R, Chiodoni C, Colombo MP, Ferrini S IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur J Immunol 2002 32 1914-1923. 

Goyos A, Robert J. Tumorigenesis and anti-tumor immune responses in Xenopus. Front Biosci. 2009 14 167-76. 

Feng F, Wang YC, Hu XB, Liu G, Chen YR, Wang L, He F, Dou GR, Liang L, Zhang HW, Han H. The transcription factor RBP-J-mediated signaling is essential for dendritic cells to evoke efficient anti-tumor immune responses in mice. Mol Cancer. 2010 9 90. 

P7-RANTES, another analog directly isolated from the initial RANTES/CCL5 library (Hartley et al., 2003), was encoded as an adjuvant in a DNA vaccine strategy and demonstrated to be capable of enhancing anti-tumor immune responses by increasing levels of local leukocyte recruitment (Dorgham et al., 2008). 

Hegardt, P, Widegren, B., Li, L., Sjogren, B., Kjellman, C., Sur, I., and Sjogren, H.O. (2001). Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol. Immunother. 50. 491-501. 

Suzuki K, Nakazato H, Matsui H, etal. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3 immmiogene therapy using a highly secretable form ofinterleukin-15 gene transfer. J Leukoc Biol 2001 69 531-537. 

Hazama S, Noma T, Wang F, et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumor immune responses in vivo. Br J Cancer 1999 80 1420-1426. 

Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation ofan anti-tumor immune response in a non-immunogenic tumour HSVt killing in vivo stimulates a mononuclear cell infiltrate and a Thl-like profile ofintratumoural cytokine expression. IntJ Cancer 1997 71 267-274. 

---